Golimumab. Inflammatory rheumatism: just another TNF alpha antagonist, no advantage.
In the absence of head-to-head comparisons with other TNF alpha antagonists, which are perfectly feasible, there is no firm evidence that golimumab has a better risk-benefit balance than other immunosuppressants.